Group No.: 1656

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Maria A. Bednarek

U.S. Serial No.: 10/500,672

Filed: July 2, 2004

For: SELECTIVE MELANIN-CONCENTRATING HORMONE

TYPE-1 RECEPTOR AGONISTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Examiner: Chih Min Kam

RECEIVED
CENTRAL FAX CENTER

MAY 18 2007

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION [37 CFR 1.321]

I. Catherine D. Fitch	05/21/2607 EHAILE1	00000046 132755 10500672 residing at
I, Catherine D. Fitch 16 Woods Hole Road, Cranford, NJ 07974	oi FC:1814 1	a representative
of the assignee identified below, empowered to act on its be Corporate Resolution No. 5, dated 04/24/2007.	half, pursuant to	o attached
The assignee, Merck & Co., Inc. that it is the assignee of the entire right, title and interest in patent application by virtue of an Assignment from the invented application, which was	the above-ident entor(s) in the a	certifies ified foresaid
recorded in the United States Patent & Trademark Offi Frame(s) 0776 on 09/26/2550		16584
was forwarded for recording on, with a and assignment attached hereto, or		
is being concurrently forwarded for recording under serecordation form and assignment attached hereto.	parate cover, wi	th a copy of the
The aforesaid assignment establishes the ownership in the a application pursuant to 37 CFR 3.73(b).	ssignee of the a	bove-identified
The undersigned has reviewed all of the evidentiary docume above-identified patent application, and the undersigned cerundersigned's knowledge and belief, title is in the assignee in the asp	tifies that, to the	of title of the best of the
I hereby disclaim the terminal part of the statutory term of a above-identified application, which would extend beyond the statutory term of:	ny patent grante ne expiration dat	ed on the te of the full
United States Patent No, or as presend disclaimer,	tly shortened by	any terminal
Any patent granted on application serial number 10/13	32,509	············ 5

PAGE 5/10 * RCVD AT 5/18/2007 12:28:01 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/14 * DNIS:2738300 * CSID: * DURATION (mm-ss):02-20

RECEIVED CENTRAL FAX CENTER

MAY 18 2007

USSN 10/500,672 Case No. 20954P

Page 2

and hereby agree that any patent so granted on the above-identified application shall be enforceable on, for and during such periods that the legal title to said patent shall be the same as the legal title to: United States Patent No. Any patent granted on application serial number 10/182,509 this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns. Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of: United States Patent No. ______, or as presently shortened by any terminal disclaimer. Any patent granted on application serial number 10/182,509 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above. The Commissioner is requested to charge Account No. 13-2755 the sum of \$130.00 and any fee deficiency required by this paper. A duplicate of this disclaimer is attached. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issuing thereon. Disclaimant Catherine D. Fitch Managing Counsel, Patents Merck & Co., Inc. In Duplicate Patent Dept., RY60-30 Attachs. P.O. Box 2000 Rahway, New Jersey 07065-0907 Date: <u>May 18, 2007</u> Telephone No. (732) 594-4283

MERCK & CO. INC.

CERTIFICATION

I, Debra A. Bollwage, Senior Assistant Secretary of Merck & Co., Inc. (the "Company"), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the attached, presently in full force and effect, is a true and correct copy of General Corporate Resolution #5, Patent Matters, as amended by Unanimous Written Consent of the Board of Directors of said Company on April 24, 2007.

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 27th day of April 2007.

Senior Assistant Segretary

(SEAL)

certifications-301

Page 1 of 1 Amended 4/24/07

General Corporate Resolution #5

PATENT MATTERS

RESOLVED, that any of the following:

Richard T. Clark-Chairman, Chief Executive Officer and President Kenneth C. Frazier-Executive Vice President and General Counsel Joseph F. DiPrima-Vice President and Assistant General Counsel Paul D. Matukaitis-Vice President and Assistant General Counsel Edward W. Murray-Managing Counsel, IP Litigation Gerard Devlin-Counsel, IP Litigation Valerie J. Camara-Managing Counsel, Patents Mark R. Daniel-Managing Counsel, Patents Catherine D. Fitch-Managing Counsel, Patents Sheldon O. Heber-Managing Counsel, Patents William Krovatin-Managing Counsel, Patents David A. Muthard-Managing Counsel, Patents Anthony Rollins-Managing Counsel, European Patents Edward M. Yoshida-Managing Counsel, Rosetta Inpharmatics Charles M. Caruso-Counsel, International Peter Haeberli-Assistant Counsel, Sirna Therapeutics, Inc. John Oksinski-Executive Director, Banyu Kenichi Osawa-Senior Director, Banyu Patent and Trademark Group Donna L. Margiotto-Senior Manager, Patent Administration

are authorized to execute and to revoke on behalf of Merck & Co., Inc. and its affiliates (including subsidiaries) the following documents relating to patent matters:

Powers of attorney as fully in law as may be necessary and proper in connection with the acquisition, registration, maintenance and enforcement of patents and applications for patents, including powers of attorney relating to the prosecution or defense of patent rights before courts of law or other governmental tribunals, agencies or departments; affidavits and declarations; and any other documents which are necessary and proper for the acquisition, registration, maintenance, litigation and protection of patents.

08053

